Logo image of BIOA

BIOAGE LABS INC (BIOA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BIOA - US09077V1008 - Common Stock

9.35 USD
+0.35 (+3.89%)
Last: 11/26/2025, 4:10:10 PM
9.35 USD
0 (0%)
After Hours: 11/26/2025, 4:10:10 PM
Fundamental Rating

3

Overall BIOA gets a fundamental rating of 3 out of 10. We evaluated BIOA against 192 industry peers in the Pharmaceuticals industry. While BIOA has a great health rating, there are worries on its profitability. BIOA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BIOA had negative earnings in the past year.
In the past year BIOA has reported a negative cash flow from operations.
BIOA Yearly Net Income VS EBIT VS OCF VS FCFBIOA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -24.53%, BIOA perfoms like the industry average, outperforming 56.25% of the companies in the same industry.
With a decent Return On Equity value of -26.81%, BIOA is doing good in the industry, outperforming 60.94% of the companies in the same industry.
Industry RankSector Rank
ROA -24.53%
ROE -26.81%
ROIC N/A
ROA(3y)-135.29%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BIOA Yearly ROA, ROE, ROICBIOA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -200 -400

1.3 Margins

BIOA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIOA Yearly Profit, Operating, Gross MarginsBIOA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for BIOA has been increased compared to 1 year ago.
Compared to 1 year ago, BIOA has an improved debt to assets ratio.
BIOA Yearly Shares OutstandingBIOA Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M
BIOA Yearly Total Debt VS Total AssetsBIOA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 5.94 indicates that BIOA is not in any danger for bankruptcy at the moment.
BIOA has a better Altman-Z score (5.94) than 79.17% of its industry peers.
BIOA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.94
ROIC/WACCN/A
WACCN/A
BIOA Yearly LT Debt VS Equity VS FCFBIOA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 13.21 indicates that BIOA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 13.21, BIOA belongs to the top of the industry, outperforming 83.33% of the companies in the same industry.
A Quick Ratio of 13.21 indicates that BIOA has no problem at all paying its short term obligations.
BIOA's Quick ratio of 13.21 is amongst the best of the industry. BIOA outperforms 83.33% of its industry peers.
Industry RankSector Rank
Current Ratio 13.21
Quick Ratio 13.21
BIOA Yearly Current Assets VS Current LiabilitesBIOA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for BIOA have decreased by -6.13% in the last year.
EPS 1Y (TTM)-6.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-51.32%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BIOA will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.34% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y72.73%
EPS Next 2Y29.73%
EPS Next 3Y18.34%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BIOA Yearly Revenue VS EstimatesBIOA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2032 5M 10M 15M 20M
BIOA Yearly EPS VS EstimatesBIOA Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BIOA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BIOA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIOA Price Earnings VS Forward Price EarningsBIOA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIOA Per share dataBIOA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

BIOA's earnings are expected to grow with 18.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.73%
EPS Next 3Y18.34%

More info and screens

0

5. Dividend

5.1 Amount

BIOA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOAGE LABS INC

NASDAQ:BIOA (11/26/2025, 4:10:10 PM)

After market: 9.35 0 (0%)

9.35

+0.35 (+3.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)03-18 2026-03-18
Inst Owners65.52%
Inst Owner Change1.89%
Ins Owners3.64%
Ins Owner Change0%
Market Cap335.20M
Revenue(TTM)3.86M
Net Income(TTM)-79.03M
Analysts51.11
Price Target9.86 (5.45%)
Short Float %1.38%
Short Ratio1.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.44%
Min EPS beat(2)-22.35%
Max EPS beat(2)33.23%
EPS beat(4)2
Avg EPS beat(4)-198.03%
Min EPS beat(4)-810.1%
Max EPS beat(4)33.23%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)107.14%
PT rev (3m)107.14%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-0.19%
EPS NY rev (3m)-0.19%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)33.28%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 86.77
P/FCF N/A
P/OCF N/A
P/B 1.14
P/tB 1.14
EV/EBITDA N/A
EPS(TTM)-9.63
EYN/A
EPS(NY)-2.61
Fwd EYN/A
FCF(TTM)-1.63
FCFYN/A
OCF(TTM)-1.6
OCFYN/A
SpS0.11
BVpS8.22
TBVpS8.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -24.53%
ROE -26.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-135.29%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 508.89%
Cap/Sales 23.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.21
Quick Ratio 13.21
Altman-Z 5.94
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)133.82%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-51.32%
EPS Next Y72.73%
EPS Next 2Y29.73%
EPS Next 3Y18.34%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-61.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.61%
EBIT Next 3Y-13.76%
EBIT Next 5YN/A
FCF growth 1Y-38.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.9%
OCF growth 3YN/A
OCF growth 5YN/A

BIOAGE LABS INC / BIOA FAQ

What is the ChartMill fundamental rating of BIOAGE LABS INC (BIOA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BIOA.


What is the valuation status for BIOA stock?

ChartMill assigns a valuation rating of 0 / 10 to BIOAGE LABS INC (BIOA). This can be considered as Overvalued.


Can you provide the profitability details for BIOAGE LABS INC?

BIOAGE LABS INC (BIOA) has a profitability rating of 1 / 10.


How financially healthy is BIOAGE LABS INC?

The financial health rating of BIOAGE LABS INC (BIOA) is 8 / 10.